£
Donate
Donate

In the project, Dr Ringhausen wants to understand more about how CLL cells can resist treatment.

Project information

Lead researcher

Dr Ingo Ringhausen, University of Cambridge

Research team
  • A team at University of Cambridge
Related conditions
  • Chronic lymphocytic leukaemia (CLL)
Research type
  • Non-clinical
Region
  • East Anglia
Grant awarded
  • Project Grant
Status
Ongoing
Funding award date
October 2022
Amount awarded

£249,149.97

The challenge

Chronic lymphocytic leukaemia (CLL) is a type of blood cancer that can be treated but cannot currently be cured. Chemotherapy is a common treatment used for people with CLL, but it’s thought that some cancerous cells get left behind after chemotherapy, causing the cancer return.

The project

Dr Ingo Ringshausen and his team think that there are non-cancerous cells that shield cancerous cells from the effects of chemotherapy, meaning those cancerous cells aren’t destroyed by treatment. He wants to understand more about how this happens.

The future

The hope is that by understanding more about this process, new treatments could be developed to reverse this and to improve the effectiveness of treatments like chemotherapy. This could improve survival for people with CLL and other types of blood cancer such as lymphoma.

This research, if successful, is very encouraging for blood cancer patients.

- Patient Voice Grant Advisory Network Member, living with non-Hodgkin lymphoma

Help us beat blood cancer by funding a research project

  • £15 could help eight people newly diagnosed with blood cancer understand their condition.
  • £30 could help researchers study blood cancer cells to develop new treatments and improve early diagnosis.
  • £50 could help scientists identify genetic patterns in tumour samples to better understand how genes contribute to the development of blood cancer.
Donate